151898-42-9

Basic information

• Product Name: 4-Chloro-6-(1-piperidinyl)-1,3,5-triazin-2-ylamine
• Synonyms: 4-Chloro-6-(1-piperidinyl)-1,3,5-triazin-2-ylamine;4-CHLORO-6-(PIPERIDIN-1-YL)-1,3,5-TRIAZIN-2-AMINE
• CAS NO: 151898-42-9
• Molecular Formula: C₈H₁₂ClN₅
• Molecular Weight: 213.66738
• Mol File: 151898-42-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 440.7±28.0 °C(Predicted)
• Appearance: /
• Density: 1.373±0.06 g/cm3(Predicted)
• PKA: 4.85±0.10(Predicted)
• CAS DataBase Reference: 4-Chloro-6-(1-piperidinyl)-1,3,5-triazin-2-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6-(1-piperidinyl)-1,3,5-triazin-2-ylamine(151898-42-9)
• EPA Substance Registry System: 4-Chloro-6-(1-piperidinyl)-1,3,5-triazin-2-ylamine(151898-42-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 151898-42-9(Hazardous Substances Data)

Upstream product

• 110-89-4 piperidine 
• 933-20-0 4,6-dichloro-1,3,5-triazin-2-amine 
• 19371-31-4 2,4-dichloro-6-piperidin-1-yl-[1,3,5]triazine 
• 108-77-0 1,3,5-trichloro-2,4,6-triazine 

Downstream Products

• 16268-88-5 4,6-di(piperidinyl)-1,3,5-triazin-2-amine 
• 26740-99-8 N-cyclohexyl-6-piperidin-1-yl-[1,3,5]triazine-2,4-diamine 

Relevant articles and documents

Hybrid Quinazoline 1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study

We report a series of hybrid quinazoline-1,3,5-triazine derivatives as EGFR inhibitors, which were synthesised and tested by using a variety of in vitro, in silico, and in vivo techniques. The derivatives were found to be active against different cancer cell lines and nontoxic against normal ones, with compounds 7 c, 7 d, 7 e, and 7 j being the most potent ones. The derivatives were also evaluated for angiogenesis inhibition potency in chicken eggs, and molecular docking and dynamics simulation studies were carried out to elucidate the fundamental substituent groups essential for their bioactivity. Additionally, a SAR study of the derivatives was performed for future compound optimisation. These studies suggested that the derivatives have a high affinity towards EGFR with favourable pharmacological properties. The most active compound (7 e) was further evaluated for in vivo anticancer activity against DMBA-induced tumours in female Sprague-Dawley rats as well as its effects on plasma antioxidant status, biotransformation enzymes, and lipid profile. The study suggested that 7 e has lead properties against breast cancer and can serve as a starting compound for further development of anti-EGFR compounds.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.